US 12,226,526 B2
Mycophenolate oral suspension
Sandip Mehta, Ahmedabad (IN); Manish Kumar Umrethia, Ahmedabad (IN); and Jayanta Mandal, Ahmedabad (IN)
Assigned to LIQMEDS WORLDWIDE LIMITED, Hayes (GB)
Filed by LIQMEDS WORLDWIDE LIMITED, Middlesex (GB)
Filed on Aug. 8, 2024, as Appl. No. 18/797,717.
Application 18/797,717 is a continuation of application No. 18/442,802, filed on Feb. 15, 2024, granted, now 12,097,285.
Application 18/442,802 is a continuation of application No. 18/362,179, filed on Jul. 31, 2023, granted, now 11,931,455, issued on Mar. 19, 2024.
Application 18/362,179 is a continuation of application No. 17/266,122, abandoned, previously published as PCT/IB2019/000987, filed on Aug. 16, 2019.
Claims priority of application No. 201821030976 (IN), filed on Aug. 18, 2018.
Prior Publication US 2024/0390268 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01)
CPC A61K 9/0053 (2013.01) [A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01)] 30 Claims
 
1. A pharmaceutical oral suspension, comprising:
mycophenolate mofetil in an amount of about 200 mg/ml;
glycerin in an amount of about 25 mg/mL to about 900 mg/ml;
one or more pharmaceutically acceptable excipients; and
water.